Thai law does not permit a foreign manufacturer to hold a drug registration or import products directly. 2 distinct licensed roles must be in place before registration begins: the Local Authorized Representative (LAR) and the Importer of Record (IOR). Getting both structured correctly is the first decision in any Thailand market-entry strategy.
The Thai Drug Act (B.E. 2510, 1967) and its subsequent amendments establish a clear principle: only a licensed Thai entity may hold a drug marketing authorization and import drugs into Thailand. A foreign manufacturer, regardless of its regulatory standing in its home country, cannot hold either license unless it operates a Thai-licensed establishment.
In practice this means every foreign manufacturer entering the Thai market must appoint at least one Thai-licensed entity to serve as its regulatory and commercial bridge. That entity bears legal responsibility to Thai FDA for everything from the initial registration submission to post-approval compliance, adverse event reporting, and license renewal.
The Drug Act requires any person or entity wishing to sell, manufacture, or import drugs into Thailand to obtain the appropriate license from Thai FDA. Government license fees range from 2,500 to 100,000 baht depending on the license type and product category.
The LAR, also referred to as the Marketing Authorization Holder (MAH), is the Thai-licensed entity that holds the drug registration in its own name on behalf of the foreign manufacturer. Thai FDA issues the marketing authorization to the LAR, not to the foreign manufacturer. The LAR is the party legally accountable to Thai FDA for the product's entire lifecycle on the Thai market.
The LAR must hold a valid establishment license issued by Thai FDA before a product license can be issued in its name. The establishment license covers the entity's legal premises and scope of activity. A lapse or suspension of the establishment license puts every product registered under it at risk.
The LAR submits the registration application, signs all submission documents, and is the named applicant on record with Thai FDA. Queries from Thai FDA during review are directed to the LAR. The LAR is responsible for ensuring responses are accurate, timely, and complete.
After approval, the LAR is responsible for maintaining the marketing authorization: submitting variation applications for any approved changes, renewing the MA before expiration, managing Thai labeling, and maintaining product information in line with the approved specifications. The LAR cannot delegate these obligations to the foreign manufacturer in a way that absolves the LAR of legal liability.
The LAR is the reporting entity for adverse drug reactions under Thai FDA's pharmacovigilance framework. Serious unexpected adverse events must be reported within defined windows. Failure to report is the LAR's legal exposure, not the foreign manufacturer's.
The LAR oversees product distribution within Thailand, including ensuring that storage, handling, and distribution conditions meet the approved specifications. Recalls, market withdrawals, and safety communications are initiated and managed by the LAR.
The LAR relationship is not a clerical arrangement. The LAR's regulatory competence, communication habits, and understanding of the foreign manufacturer's product are directly reflected in the quality of every Thai FDA interaction. The choice of LAR is the most consequential structural decision a foreign manufacturer makes in Thailand.
Before appointment, confirm that the prospective LAR holds a current, valid establishment license with a scope that covers importation and distribution of the relevant drug category. An LAR whose license is under renewal, restricted, or does not cover the correct drug category cannot legally hold your marketing authorization.
The LAR must have the internal capability to prepare ACTD dossiers, respond to Thai FDA queries in Thai, manage variation submissions, and maintain the pharmacovigilance system. An LAR that outsources all technical work without maintaining oversight is a structural liability.
Thai FDA correspondence is conducted in Thai. The LAR's ability to communicate accurately and promptly in both Thai and English determines how well the foreign manufacturer stays informed. An LAR that filters, delays, or softens communications to manage the relationship is a common root cause of timeline overruns.
The commercial agreement between the foreign manufacturer and its LAR should clearly define authority over dossier content, variation decisions, label claims, and recall authority. Ambiguity in these areas leads to disputes at the worst possible time: during a Thai FDA review or a post-market safety event.
The Importer of Record is the Thai-licensed entity named on the import documentation for each physical shipment entering Thailand. The IOR is distinct from the LAR in function, though in practice the same entity often holds both roles. The IOR must hold an establishment license that specifically covers drug importation activity.
Physical importation of drugs into Thailand requires a separate import permit issued per product and per approved shipment. The IOR applies for and holds this permit. The permit is product-specific: a permit issued for one product does not cover another, even if the IOR is the same entity. Commercial shipments cannot proceed without a valid, current import permit.
The drug import license held by the IOR is valid from January 1 to December 31 of each calendar year and must be renewed annually. Unlike the marketing authorization, which runs for 7 years, the import license does not persist automatically. An IOR that fails to renew on time cannot legally receive shipments until the renewed license is in place.
At each importation event, the IOR must present the current import permit, the approved labeling, and any required quality documentation (such as a certificate of analysis from the manufacturer). Thai Customs coordinates with Thai FDA on drug importation; discrepancies between the shipment and the approved documentation will hold the goods.
The IOR is responsible for ensuring that imported products are received, stored, and handled in conditions consistent with the approved product specifications from the point of import. Cold-chain products require verified storage capacity before the first shipment arrives.
In many market-entry structures, the same Thai-licensed entity holds both the LAR/MAH role and the IOR role. This is common and often simpler to manage: a single counterpart holds both the marketing authorization and the import license, coordinates both regulatory and logistics functions, and is the single point of accountability to Thai FDA and to the foreign manufacturer.
Separate LAR and IOR arrangements are used when the foreign manufacturer has an established distribution partnership in Thailand for logistics but requires a different entity for the regulatory and dossier work. This structure introduces coordination requirements: the LAR and IOR must align on import permit applications, labeling, and product documentation at each shipment event. When these two entities do not communicate reliably, shipments are held and timelines slip.
The right structure depends on what licensed entities are available to the foreign manufacturer, the complexity of the product portfolio, and the nature of the distribution arrangement. There is no single correct answer, but the cost of a poorly structured arrangement is high and difficult to correct after registration is approved.
VeroPharma Group serves as LAR and IOR for foreign manufacturers entering the Thai pharmaceutical market. We hold the establishment licenses required for both roles and manage the full regulatory and importation function in-house.
We do not subcontract the dossier work, the Thai FDA correspondence, or the import permit process. Every submission that goes to Thai FDA under our name is prepared and reviewed by our senior regulatory team. We communicate in Thai and in English, and we give our clients a clear, accurate picture of where their registration stands at every stage.
For manufacturers who already have a local distribution partner and need only the regulatory LAR function, we can structure that separately. We tell clients what will and will not work before they commit.